ClinicalTrials.gg
CompletedNCT06296953PeriSaFe01Updated Sep 19, 2024

Safety & Feasibility of PERIsign System in Demonstrating Involuntary Muscle Defense as a Sign of Peritonitis in Subjects With Appendicitis

An interventional study of PERIsign examination in Appendicitis Acute, Appendicitis and Abdominal Pain, sponsored by STB INN AB. Completed at 2 sites in Sweden. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-09-19.

Sponsored by STB INN AB · Not applicable, Interventional, and Diagnostic

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Non-randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

This will be an explorative, proof-of-principle, open, multi-center investigation.

The investigation aims to investigate the safety of the PERIsign system and the ability of physicians to differentiate between healthy individuals and subjects with involuntary muscle defense as a sign of peritonitis by utilizing PERIsign data. The investigation will include a total of 20 subjects admitted to hospital for suspected appendicitis and planned for emergency surgery and 20 healthy volunteers. Both male and female subjects aged 18-70 years will be enrolled.

All subjects will undergo PERIsign examinations. Subjects with suspected appendicitis will undergo 1-2 PERIsign examinations before their planned appendectomy surgery. For the healthy volunteers, there is only 1 PERIsign examination. During each examination, 4 PERIsign curves will be obtained, one from each quadrant of the abdomen. The attending physician will interpret the appearance of the PERIsign curves of all subjects, including those from the healthy volunteers. The duration of the PERIsign examination will be documented, and usability data will be gathered, including the need for sensor adjustments, subject perception of the examination, and any discomfort experienced. In addition, blinded physicians will evaluate all subjects' PERIsign curves and determine whether each subject has involuntary muscle defense as a sign of peritonitis. These blinded physicians will have access to all 4 PERIsign curves obtained during each examination, while other data will not be disclosed to them.

Safety will be evaluated through analysis of reported adverse events and device deficiencies

Read the detailed description

METHODOLOGY The PERIsign system is intended to aid physicians in demonstrating involuntary muscle defense as a sign of peritonitis by assessing involuntary activity in abdominal muscles by use of sEMG sensors and induced pressure.

In this investigation, all subjects will undergo examinations with the PERIsign system. For subjects with suspected appendicitis, assessments will be performed at the clinic on up to 2 occasions. An initial examination will occur when the patient is scheduled for surgery and admitted to the hospital. The following examination is optional and will occur 4-6 hours after the initial examination but before their planned surgery. Post-operative clinical assessments, patho-anatomical diagnosis and clinical end diagnosis will be collected from medical journals, 30 ±5 days after the initial examination. For the healthy volunteers, there is only 1 examination.

INVESTIGATIONAL MEDICAL DEVICE The PERIsign system is a medical device designed to measure the contractions of the internus and externus oblique muscles in the abdomen by use of surface electromyography (sEMG) sensors and induced pressure to facilitate the evaluation of a patient with acute abdominal pain. The PERIsign system aims to aid physicians in demonstrating involuntary muscle defense as a sign of peritonitis, an inflammation of the peritoneum, by measuring muscle activity both at rest and in response to pressure on the abdominal wall.

The PERIsign Minimal Viable Product is the first iteration of the device and will be used for the present clinical investigation. It comprises four sensor heads with connections, used together with single use sensor electrodes, that are applied to four specific locations on the patient's abdomen, and one reference electrode attached to the hand. Each sensor head has a pressure sensor on top that measures the pressure applied to the sensor, mimicking the manual palpation performed by a physician. The PERIsign system will display and record the patient's muscle activity and the pressure being applied to their abdomen. PERIsign is connected to a laptop for data collection.

02

Conditions studied

  • Appendicitis Acute
  • Appendicitis
  • Abdominal Pain
  • Peritonitis

Keywords

  • Appendicitis
  • Acute abdominal pain
  • Peritonitis
  • Medical Device
  • PERIsign
03

In context

Appendicitis

419 studies on the registry are indexed under Appendicitis; 67 are open to participants now.

This study's enrollment of 40 is below the median of 111 across 252 interventional studies indexed under Appendicitis.

Browse Appendicitis studies →

Lead sponsor

This is the only study on the registry with STB INN AB as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:

Inclusion criteria for healthy volunteers

For enrolment in the investigation, healthy volunteers must fulfil all the following criteria:

  1. Subject is 18-70 years of age
  2. The subject reports having understood and has signed the Form (ICF) and is willing to comply with all assessments
  3. The subject should have a sufficient height and physical build to enable the attachment of the PERIsign sensors to their abdomen, as judged by the Investigator Inclusion criteria for the patient group

For enrolment in the investigation, patients must fulfil all the following criteria:

  1. Patient is 18-70 years of age
  2. The patient reports having understood and has signed the ICF and is willing to comply with all assessments
  3. The patient is admitted to the hospital with suspected appendicitis and scheduled for emergency surgery within 24 hours.
  4. Patient is deemed clinically stable, as judged by the Investigator
  5. The patient should have a sufficient height and physical build to enable the attachment of the PERIsign sensors to their abdomen, as judged by the Investigator

Exclusion Criteria:

Exclusion criteria for healthy volunteers

Healthy volunteers meeting any of the following criteria will not be permitted to enter the investigation:

  1. >30
  2. Presence of any known pathological diseases in the abdomen
  3. Subject who previously underwent abdominal surgery
  4. Subject with spinal cord injury
  5. Subject with pacemaker
  6. Pregnancy at the time of enrollment, as confirmed by either knowledge or a urine test
  7. The subject has a cognitive incapacity or language barrier precluding adequate understanding or cooperation
  8. The subject is considered by the Investigator to be unsuitable to participate in the investigation for any other reason
  9. Subject already enrolled (within 30 days prior to enrolment) in another drug/s or device/s clinical study Exclusion criteria for the patient group

Patients meeting any of the following criteria will not be permitted to enter the investigation:

  1. BMI >30
  2. Patient who previously underwent abdominal surgery
  3. The patient is currently undergoing therapy, including systemic treatment for two weeks prior to enrollment
  4. Patient with spinal cord injury
  5. Patient with pacemaker
  6. Known abdominal ventral hernia
  7. Known abdominal rectus muscle diastasis
  8. Retrocecal appendix according to radiology
  9. Other known pathological conditions of the abdomen that may interfere with the performance, evaluation and outcome of the clinical evaluation, as determined by the Investigator
  10. The patient must not be pregnant at the time of enrollment, as confirmed by either prior knowledge or a urine test
  11. The patient has a cognitive incapacity or language barrier precluding adequate understanding or cooperation
  12. The patient is considered by the Investigator to be unsuitable to participate in the investigation for any other reason
  13. The PERIsign examination is deemed to interfere with the standard of care
  14. Subject already enrolled (within 30 days prior to enrolment) in another investigational drug/s or device/s clinical study -
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Patient Group

    Patient will be examined with the new device, PERIsign.

    Device: PERIsign examination

  • Active comparator
    Healthy Volunteers

    The group will also be examined with the device, PERIsign

    Device: PERIsign examination

Interventions

  • DevicePERIsign examination

    Patients will be examined with the new device, PERIsign

06

What researchers measure

Primary outcomes

  1. Proportion of subjects experiencing any adverse events during the examination

    Evaluation of there is any adverse events during the examination of the new diagnostic device.

    Time frame: 1 hour

  2. Proportion of device deficiencies during the evaluation

    Evaluation of there is any device deficiencies during the examination of the new diagnostic device.

    Time frame: 1 hour

Secondary outcomes

  1. To estimate the sensitivity and specificity of diagnosing pathological muscle defense when using the PERIsign system

    During the evaluation the examiner interprets the graphical curves presented by the PERIsign system to evaluate and determine if there is an involuntary muscle defense at the subjects abdominal wall. The sensitivity and specificity will be calculated.

    Time frame: 1 hour

  2. Proportion of examinations of the PERIsign system that its performed without usability issues.

    The usability of the PERIsign system is tested by measuring how long the examination will take and how easy it is to use bye the examiner.

    Time frame: 1 hour

07

Study locations

2 sites
  • Hallands Sjukhus Halmstad
    Halmstad, Sweden
  • Hallands Sjukhus Varberg
    Varberg, Sweden
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2024 to primary completion in Aug 2024, 4 months.

Of 91 interventional studies with no phase under Appendicitis, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 36. This study's 4 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 10, 2024
First posted
Mar 6, 2024
StartActual
Mar 15, 2024
Primary completionActual
Aug 1, 2024
CompletionActual
Aug 1, 2024
Last update
Sep 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06296953
Lead sponsor
STB INN AB
Collaborators
Scandinavian CRO, Region Halland
Responsible party
Sponsor
First posted
Mar 6, 2024
Start date
Mar 15, 2024
Primary completion
Aug 1, 2024
Completion
Aug 1, 2024
Last update
Sep 19, 2024

Study contacts

Stefan Lindskog, ass. Prof
principal investigator · Region Halland

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion